We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
Read MoreHide Full Article
Shares of Phio Pharmaceuticals (PHIO - Free Report) rallied 52.5% on Wednesday after the company announced that the Safety Monitoring Committee (SMC) has recommended dose escalation in an early-stage study of the company’s investigational skin cancer candidate, PH-762.
PH-762 is Phio Pharmaceuticals’ lead and only clinical-stage candidate, which is being developed leveraging its proprietary Intasyl siRNA gene silencing technology to eliminate cancer. The phase Ib dose escalation study is evaluating the safety and tolerability of neoadjuvant use of intratumoral PH-762 for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.
The SMC’s decision allowing escalation to the next dose concentration was based on the favorable safety profile of the drug observed in the third cohort of the phase Ib study, which enrolled three patients with cutaneous squamous cell carcinoma. In these patients, injections were well tolerated, with no serious adverse events or dose-limiting toxicities. Pathology results assessing the efficacy of PH-762 in the third cohort are also expected soon.
Year to date, shares of Phio Pharmaceuticals have lost 14.4% compared with the industry’s 9.7% decline.
Image Source: Zacks Investment Research
PHIO’s Skin Cancer Drug Effective in Previous Dosing Cohorts
In earlier dosing cohorts, PH-762 demonstrated promising efficacy in patients with cutaneous carcinomas. Among the seven patients treated in the first two cohorts, four were diagnosed with cutaneous squamous cell carcinoma. Notably, in the second cohort, tumor excision at Day 36 revealed a complete response (100% tumor clearance) in two patients and a partial response (90% clearance) in another. Additionally, all three patients from cohort 1 and one from cohort 2 maintained stable disease.
Based on these results, management believes that PH-762 has the potential to become an effective non-surgical alternative to existing modes of therapy for skin cancer, subject to successful development.
Phio Pharmaceuticals also has another candidate, PH-894, in its pipeline, which is currently in the preclinical stage. PH-894, a BRD4 protein silencer, is also being developed utilizing the Intasyl siRNA gene silencing technology for various cancer indications. However, following a recent strategic reprioritization, the company has decided to focus on the development of PH-762 for skin cancers in the United States.
In the past 30 days, estimates for Bayer’s earnings per share have increased from $1.17 to $1.19 for 2025. During the same time, earnings per share have increased from $1.27 to $1.28 for 2026. Year to date, shares of Bayer have gained 17.4%.
BAYRY’s earnings matched estimates in two of the trailing three quarters while missing the same on the remaining occasion, the average negative surprise being 19.61%.
In the past 30 days, estimates for Dynavax’s earnings per share have remained constant at 33 cents for 2025. During the same time, earnings per share have remained constant at 57 cents for 2026. Year to date, shares of DVAX have lost 5.8%.
DVAX’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 9.58%.
In the past 30 days, the estimate for ADMA Biologics’ 2025 earnings per share has increased from 70 cents to 71 cents. The estimate for 2026 earnings per share has remained constant at 93 cents. Year to date, shares of ADMA Biologics have gained 13.1%.
ADMA’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 32.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
Shares of Phio Pharmaceuticals (PHIO - Free Report) rallied 52.5% on Wednesday after the company announced that the Safety Monitoring Committee (SMC) has recommended dose escalation in an early-stage study of the company’s investigational skin cancer candidate, PH-762.
PH-762 is Phio Pharmaceuticals’ lead and only clinical-stage candidate, which is being developed leveraging its proprietary Intasyl siRNA gene silencing technology to eliminate cancer. The phase Ib dose escalation study is evaluating the safety and tolerability of neoadjuvant use of intratumoral PH-762 for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.
The SMC’s decision allowing escalation to the next dose concentration was based on the favorable safety profile of the drug observed in the third cohort of the phase Ib study, which enrolled three patients with cutaneous squamous cell carcinoma. In these patients, injections were well tolerated, with no serious adverse events or dose-limiting toxicities. Pathology results assessing the efficacy of PH-762 in the third cohort are also expected soon.
Year to date, shares of Phio Pharmaceuticals have lost 14.4% compared with the industry’s 9.7% decline.
Image Source: Zacks Investment Research
PHIO’s Skin Cancer Drug Effective in Previous Dosing Cohorts
In earlier dosing cohorts, PH-762 demonstrated promising efficacy in patients with cutaneous carcinomas. Among the seven patients treated in the first two cohorts, four were diagnosed with cutaneous squamous cell carcinoma. Notably, in the second cohort, tumor excision at Day 36 revealed a complete response (100% tumor clearance) in two patients and a partial response (90% clearance) in another. Additionally, all three patients from cohort 1 and one from cohort 2 maintained stable disease.
Based on these results, management believes that PH-762 has the potential to become an effective non-surgical alternative to existing modes of therapy for skin cancer, subject to successful development.
Phio Pharmaceuticals also has another candidate, PH-894, in its pipeline, which is currently in the preclinical stage. PH-894, a BRD4 protein silencer, is also being developed utilizing the Intasyl siRNA gene silencing technology for various cancer indications. However, following a recent strategic reprioritization, the company has decided to focus on the development of PH-762 for skin cancers in the United States.
Phio Pharmaceuticals Corp. Price and Consensus
Phio Pharmaceuticals Corp. price-consensus-chart | Phio Pharmaceuticals Corp. Quote
PHIO Zacks Rank & Stocks to Consider
Phio Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the sector are Bayer (BAYRY - Free Report) , Dynavax Technologies Corporation (DVAX - Free Report) and ADMA Biologics (ADMA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
In the past 30 days, estimates for Bayer’s earnings per share have increased from $1.17 to $1.19 for 2025. During the same time, earnings per share have increased from $1.27 to $1.28 for 2026. Year to date, shares of Bayer have gained 17.4%.
BAYRY’s earnings matched estimates in two of the trailing three quarters while missing the same on the remaining occasion, the average negative surprise being 19.61%.
In the past 30 days, estimates for Dynavax’s earnings per share have remained constant at 33 cents for 2025. During the same time, earnings per share have remained constant at 57 cents for 2026. Year to date, shares of DVAX have lost 5.8%.
DVAX’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 9.58%.
In the past 30 days, the estimate for ADMA Biologics’ 2025 earnings per share has increased from 70 cents to 71 cents. The estimate for 2026 earnings per share has remained constant at 93 cents. Year to date, shares of ADMA Biologics have gained 13.1%.
ADMA’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 32.8%.